Cardiac Events after Treatment with High-Dose Radiation Therapy +/– Chemotherapy for Non-Small Cell Lung Cancer
L. Tang,A. Liu,D. R. Gomez,Q. Nguyen,T. Xu,R. U. Komaki,Z. Liao
DOI: https://doi.org/10.1016/j.ijrobp.2014.05.653
2014-01-01
Abstract:Cardiac events after high-dose radiation therapy (RT) for non-small cell lung cancer (NSCLC) have not been reported comprehensively. We performed a detailed analysis of cardiac toxicity that occurred in a cohort of patients treated with definitive doses of RT in this context. This study included 303 NSCLC patients who received RT (dose ≥ 60 Gy) from April 1, 2004 through May 31, 2010 at a single institution. The median radiation prescription dose was 70 Gy (range, 60-87.5 Gy). The median value of the mean heart dose (MHD) was 11.4 Gy (range, 0-52.4 Gy). Thirty-two percent of patients (n = 96) received induction chemotherapy, 84.8% (n = 257) received concurrent chemotherapy, and 20.8% (n = 63) received adjuvant chemotherapy. Pre-existing cardiac conditions included myocardial ischemia in 15.8% of patients (n = 48), arrhythmia in 9.9% (n = 30), hypertension in 49.5% (n = 150), and diabetes mellitus in 13.2% (n = 40). Cardiac toxicity was defined as having any previously undocumented cardiac event occurring after the start of radiation therapy, and was classified into five categories: myocardium ischemia, pericarditis, arrhythmia, heart failure, and valve abnormalities, each scored according to the CTCAE v4.0 system. Patients that were diagnosed with new cardiac events after RT were compared with those that were not using the chi-squared test. Then, the cumulative incidence of each category of cardiac events according to different MHD was compared using the log-rank test. Fifty-three percent of patients (n = 161) in the entire patient cohort were found to have a new cardiac diagnosis after RT. The incidence of new-onset myocardial ischemia, pericarditis, arrhythmia, heart failure and valve abnormalities were 5.6%, 39.3%, 11.9%, 4.0%, and 17.2%, respectively. The median time to develop grade 2 or above myocardial ischemia, pericarditis, arrhythmia, heart failure, and valve abnormalities was 8.8, 8.6, 7.7, 4.8, and 9.6 months, respectively. Patients with new cardiac diagnoses after RT did not differ from those without new cardiac events with respect to age, sex, stage (I-II vs III-IV vs recurrence), laterality of tumor (right vs left), smoking, alcohol history, prior cardiac disease, or RT technique (p > 0.05 for all). With regard to specific cardiac events, the use of concurrent chemotherapy and adjuvant chemotherapy (OR = 2.31, 95% CI: 1.12-4.74, p = 0.02; OR = 2.14, 95% CI: 1.22-3.75, p = 0.01) was associated with pericarditis, while a MHD of 22.6 Gy or higher was correlated with the cumulative incidence of post-RT myocardial ischemia (p = 0.02). The incidence of developing cardiac events after high-dose RT for NSCLC is approximately 50%, with the most common events being myocardial ischemia, pericarditis, and arrhythmia. Treatment-specific correlations with specific event types may be due to differing mechanisms of each of these modalities.